Key Highlights

  • On Tuesday, November 17, 2026 shares were trading 46.15% higher at USD 2.66, about 1.5% shy (calculated) of the cash offer that Rosemont Pharmaceuticals Holdings put at USD 2.70 a share.
  • Rosemont puts the deal at near USD 56 million fully diluted, and published coverage cites a 51.7% premium to the November 13 close and a 41.1% premium to the 30-day volume-weighted average price.
  • Late December 2026 is the targeted close, with a majority of shares tendered required; published coverage adds that either party may walk away if the deal is unfinished by February 14, 2027, and a USD 2.4 million termination fee applies in certain cases.
  • First-quarter fiscal Revenue reached USD 14.8 million versus USD 13.9 million a year before, with a USD 3.9 million net loss, USD 25.5 million of cash and ADHD portfolio revenue falling from USD 13.2 million to USD 7.7 million.

A USD 2.70 Cash Tender Offer Anchors the Share Price

Shares of Aytu BioPharma (NASDAQ:AYTU) were trading 46.15% higher at USD 2.66 on Tuesday, November 17, 2026. The catalyst arrived in a November 16, 2026 announcement, in which Rosemont Pharmaceuticals Holdings said it would pay USD 2.70 in cash for each share, roughly USD 56 million on a fully diluted basis under the treasury stock method. A prior close near USD 1.82 is implied by the screener move, while the 51.7% premium in published coverage starts from the November 13 close; the two bases therefore differ slightly. The company markets prescription drugs aimed at the central nervous system and pediatric segments, including EXXUA for major depressive disorder and ADHD treatments.

The Two-Step Structure and the Hurdles Before the Deal Completes

A tender offer comes first, with a Merger to follow. Rosemont's Acquisition Subsidiary must submit a Schedule TO to the SEC and start the offer; published coverage says that should happen within 10 Business days of signing, with the offer open for 20 days unless it is extended. In response, Aytu BioPharma (NASDAQ:AYTU) will file a Schedule 14D-9 that carries its board's recommendation. Per the release, a majority of outstanding shares must be tendered, and published coverage adds a limit of 15% on warrants, by underlying shares, left unexercised and untendered. Any shares not tendered would be converted into the same cash through a Delaware merger with no further vote. Management expects completion by the end of calendar 2026.

Fiscal First-Quarter Results, the ADHD Slide and What Could Derail the Sale

Fiscal 2027 first-quarter results came out on November 16, 2026, showing USD 14.8 million of revenue against USD 13.9 million and a USD 3.9 million net loss. Adjusted EBITDA was a USD 2.6 million loss compared with a USD 0.6 million loss. Cash of USD 25.5 million sat against roughly USD 16.5 million of Debt (calculated from revolver and term debt). ADHD portfolio revenue fell from USD 13.2 million down to USD 7.7 million, and EXXUA contributed USD 4.9 million. One source of published coverage says officers, directors and affiliates tied to Nantahala Capital Management and Stonepine Capital Management agreed to tender; their combined stake was not disclosed. A failed condition or a slip past February 14, 2027 are the main risks.

Where Things Stand

The rally reflects a cash Takeover offer and not an operating recovery. Aytu BioPharma (NASDAQ:AYTU) sits about 1.5% under the USD 2.70 price (calculated), a gap that usually prices in waiting time and the chance the deal fails. Next markers are the launch of Rosemont's tender, the board recommendation filing, the number of shares tendered and any regulatory or Warrant conditions, with completion aimed at late December 2026. A few trades can move the price, and quotes can reverse if terms change.